ENDORET® PRGF®
A standardised autologous platelet-rich plasma technology for multispecialty clinical use
Developed by BTI Biotechnology Institute, Endoret® (PRGF®) uses a defined preparation, fractionation and activation protocol to produce leukocyte-free plasma formulations for use by trained healthcare professionals across multiple clinical specialities.
What is Endoret® (PRGF®)
Endoret® (PRGF®) is a proprietary platelet-rich plasma technology. It combines system-specific blood collection components, controlled centrifugation, defined plasma fractionation and calcium chloride activation. This protocol-led approach is designed to improve preparation consistency and enables clinicians to select different PRGF® formulations according to the intended clinical use.
Endoret® belongs to the wider platelet-rich plasma category, but platelet preparations are not interchangeable. PRP systems can differ in cellular composition, platelet concentration, centrifugation, anticoagulation, activation and final formulation. These differences may affect biological behaviour and make system-specific evidence important.
A defined preparation process
1
Blood collection
A sample of the patient’s blood is collected using the components specified for the Endoret® system.
2
Controlled centrifugation
The sample is processed using the Endoret® centrifuge and the preparation parameters defined by the manufacturer.
3
Plasma fraction selection
The required plasma fraction is separated from the red blood cell and leukocyte layers according to the intended formulation.
4
Controlled activation
Calcium chloride is added according to the protocol to initiate platelet activation, growth factor release and fibrin formation where required.
System characteristics
Defined preparation protocol
System-specific components and preparation steps support a consistent clinical workflow.
Leukocyte-free formulation
The selected plasma is prepared without leukocytes, limiting exposure to leukocyte-derived pro-inflammatory mediators.
Controlled activation
Calcium chloride activation initiates platelet degranulation and allows the timing and physical form of the preparation to be managed according to the protocol.
Multiple formulations
The system can provide liquid and fibrin-based formulations for different clinical settings, subject to the current instructions for use.
Training and implementation support
Sovereign Medical provides equipment guidance, practical training and ongoing product support for clinical teams.
Patient advantages of Rejoint
Use this space to promote the business, its products or its services. Help people become familiar with the business and its offerings, creating a sense of connection and trust. Focus on what makes the business unique and how users can benefit from choosing it.
Improved functionality
Significantly enhances limb function by restoring joint mobility.
Item Title
Decreases pain during movement, improving quality of life.
Item Title
As a bioabsorbable implant, RegJoint™ eliminates the need for removal surgeries.
Item Title
Describe the item here. Include important features, pricing and other relevant info.
Biological rationale
Platelets and plasma contain bioactive proteins involved in normal tissue repair. Following activation, the selected PRGF® preparation releases mediators including platelet-derived growth factor, transforming growth factor beta, vascular endothelial growth factor, insulin-like growth factor 1 and fibroblast growth factor.
These mediators are involved in processes such as cell migration, proliferation, angiogenesis, extracellular matrix production and inflammatory signalling. The biological response and clinical outcome can vary according to the patient, tissue, condition and application.
Orthopaedics and Osteoarthritis
Explore the use of protocol-led PRGF® formulations in joint, bone and musculoskeletal care.
Sports Medicine
Review applications being investigated across tendon, ligament, muscle and sports-related care.
Wound Care
Learn how liquid and fibrin-based PRGF® formulations may be incorporated into selected wound-management pathways.
Plastic and Reconstructive Surgery
Explore biological support for selected surgical wounds, grafts and soft-tissue procedures.
Dermatology Aesthetics and Hair
Review applications being investigated in skin quality, scars, procedural recovery and hair-related care.
Reproductive Medicine
Read about the standardised PRGF® preparation being investigated as an adjunct in selected reproductive medicine settings.
Clinical Evidence
Endoret® (PRGF®) has been investigated in published preclinical and clinical research across several medical and surgical specialities. The type and strength of evidence vary by indication, and findings should be interpreted according to the specific preparation, patient population, comparator and clinical outcome studied.
Our evidence library organises relevant research by speciality and presents study design, population, outcomes and limitations to support informed professional review.